SCHEDULE: Vestal Point Capital Discloses 1.5% Stake in KalVista
Beneficial Ownership Disclosure
Vestal Point Capital, LP and Ryan Wilder have reported a 1.5% beneficial ownership stake in KalVista Pharmaceuticals, Inc., holding 750,000 shares.
Summary
- Vestal Point Capital, LP and Ryan Wilder collectively beneficially own 750,000 shares of KalVista Pharmaceuticals, Inc. Common Stock.
- This ownership represents 1.5% of the total 50,523,274 shares of Common Stock outstanding as of August 29, 2025.
- The shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of KalVista Pharmaceuticals, Inc.
- Both Vestal Point Capital, LP and Ryan Wilder share voting and dispositive power over the 750,000 shares.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine ownership disclosure and does not contain performance or strategic information.
Key Dates
| Date | Description |
|---|---|
| 2025-07-31 | End of quarterly period for which KalVista's 10-Q reported shares outstanding. |
| 2025-08-29 | Date as of which 50,523,274 shares of Common Stock were outstanding. |
| 2025-09-30 | Date of event requiring the filing of this statement. |
| 2025-11-14 | Signature date of the Schedule 13G filing. |
Keywords
KalVista Pharmaceuticals, Vestal Point Capital, Ryan Wilder, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.